Cart
sales@molnova.com
TL-895
CAS No. 1415823-49-2
TL-895( —— )
Catalog No. M28845 CAS No. 1415823-49-2
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 89 | In Stock |
|
| 25MG | 181 | In Stock |
|
| 50MG | 275 | In Stock |
|
| 100MG | 405 | In Stock |
|
| 200MG | 574 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTL-895
-
NoteResearch use only, not for human use.
-
Brief DescriptionTL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.
-
DescriptionTL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1415823-49-2
-
Formula Weight447.5
-
Molecular FormulaC25H26FN5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (558.66 mM)
-
SMILESC=CC(N(CC1)CCC1(CNc1ncnc(N)c1-c(cc1)ccc1Oc1ccccc1)F)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meier, U.T., Kronbach, T., and Meyer, U.A. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 151(2), 286-291 (1985).
molnova catalog
related products
-
BTK inhibitor 17
BTK inhibitor 17 is a potent irreversible BTK inhibitor (IC50 = 2.1 nM). BTK inhibitor 17 can be used in rheumatoid arthritis studies.
-
QL-47
A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM.
-
Atuzabrutinib
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
